key: cord-0301780-yrp9tvl7
authors: Hatcher-Martin, J.; McKay, J. L.; Sommerfeld, B.; Howell, J. C.; Goldstein, F. C.; Factor, S. A.
title: Cerebrospinal fluid Ab42 and fractalkine are associated with Parkinson's disease with freezing of gait
date: 2020-12-18
journal: nan
DOI: 10.1101/2020.12.16.20248342
sha: 558e479aa4cd70e27f30c0307906f59b3c6083cc
doc_id: 301780
cord_uid: yrp9tvl7

Objective: To evaluate the association of Alzheimer's disease-related and inflammation-related cerebrospinal fluid (CSF) markers with freezing of gait (FOG) in patients with Parkinson's disease (PD). Methods: The study population included well-characterized PD patients with FOG (PD-FOG), without FOG (PD-NoFOG) and healthy controls (HC). CSF was collected using standard protocols. Three Alzheimer's disease-related markers and 10 inflammation-related markers were measured in a Luminex 200 platform. Differences in marker expression across groups were evaluated with multivariate linear models. Results: CSF was collected from PD-FOG (N=12), PD-NoFOG (N=20) and HC (N=11) for analysis. Age was not significantly different between the three groups. Duration of PD was not significantly different between the two PD groups. After adjusting for covariates and multiple comparisons, the anti-inflammatory marker, fractalkine, was significantly decreased in the PD groups compared to HC (P=0.022), and further decreased in PD-FOG compared to PD-NoFOG or HC (P=0.032). The Alzheimer's disease-related protein, A{beta}42, was increased in PD-FOG compared to PD-NoFOG or HC (P=0.004). p-Tau181 was also decreased in both PD groups compared to HC (P=0.010). Conclusions: We found high levels of A{beta}42 in PD-FOG patients and cross-sectional data which supports an increase over time from early to advanced state. We also found low levels of fractalkine which might suggest anti-inflammatory effect. This is the first time an association between fractalkine and FOG has been shown. Whether these changes are specific to FOG requires further exploration.

Freezing of gait (FOG) is characterized by arrests of stepping when initiating gait, turning, and walking straight ahead and patients describe it as their feet being "glued" to the floor 1 . While it is a well-known feature of PD, it has been reported in other parkinsonian disorders as well 2 . FOG frequency in PD patients increases with disease duration and occurs in >60% of patients with >/=10 years of disease 3 . It is a gait symptom complex that has potentially grave consequences 1, 4 as it is unpredictable in character, a leading cause of falls with injury, and results in loss of independence and social isolation. Treatment options are limited 1, 5 . Although FOG is considered to be a cardinal feature of PD, it appears to develop and/or progress independently of the other cardinal motor features 6 . It is associated with specific clinical risk factors (longer disease duration, psychotic symptoms, and absence of tremor), is associated with cognitive change and is thought to be caused by specific as yet unknown pathology 7,8 9 . The pathophysiology of FOG remains poorly understood. The literature shows great variability in findings related to physiological and imaging research, as well as motor and non-motor correlates and therapeutic response to various treatment modalities 8, [10] [11] [12] suggesting it possibly relates to a circuit change.

There has been little in the way of biofluid research in FOG. One study of data from the Parkinson Progression Marker Initiative study (PPMI) showed that low CSF β-amyloid42 (Aβ42) levels in early PD predicted incident FOG within the first few years after diagnosis 13 using measures from the Movement Disorder Society-Unified Parkinson's disease Rating Scale (MDS-UPDRS) and this has been supported by increased neocortical deposition of β-amyloid in brain with imaging studies 14 . However, these data have been reported only for the first three years after disease onset. In this study we present initial results of CSF analysis in PD patients . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 18, 2020. ; https://doi.org/10.1101/2020. 12.16.20248342 doi: medRxiv preprint with and without FOG and aged-matched healthy controls. We also present results describing variation in CSF markers over a wide range of disease duration (onset-23 years).

CSF samples were collected from PD-FOG (N=12), PD-NoFOG (N=20) and HC (N=11) for analysis. Age was not significantly different for the three groups and duration of PD was not significantly different for the PD-FOG and PD-NoFOG groups. The HC group included more females than either of the PD groups: 73% female in the HC group, 35% PD-NoFOG group and 8% PD-FOG group ( Table 1) .

Levels of CSF markers that varied across groups are summarized in Table 2 . Expression of all CSF markers entered into analyses are summarized in Table S2 . Initial univariate analyses identified four CSF markers associated with PD (p-Tau 181 , fractalkine, TGFα, MCP-1) and two CSF markers associated with PD-FOG (fractalkine, Aβ42). After adjustment for multiple comparisons and covariates (Figure 1 ), the anti-inflammatory marker, fractalkine, was significantly decreased in PD-NoFOG compared to HC (P=0.022, adjusted), and further decreased in PD-FOG compared to PD-NoFOG or HC (P=0.032, adjusted). The AD-related protein, Aβ42, was significantly increased in PD-FOG compared to PD-NoFOG or HC (P=0.004, adjusted). p-Tau 181 was also significantly decreased in all PD compared to HC (P=0.010, adjusted) with no difference between those with and without FOG. No statistically . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 18, 2020. ; https://doi.org/10.1101/2020.12.16.20248342 doi: medRxiv preprint significant effects of gender or PD duration were identified in models that were statistically significant for PD-NoFOG or PD-FOG, either before or after Holm adjustment.

The association between each marker identified in initial multivariate analyses as varying across groups and PD duration is shown in Figure 2 . There was a significant linear relationship (P=0.02) between Aβ42 expression and PD duration with significant (P=0.005) interaction between the PD-FOG and PD-NoFOG groups in multivariate models controlling for age and sex.

Aβ42 increased with increasing duration in the PD-FOG group but decreased with increasing duration in the PD-NoFOG group. No other statistically significant associations were identified.

Visual inspection of plots indicated some evidence of interaction between groups for fractalkine, in which the PD-FOG group decreased with increasing duration whereas the PD-NoFOG group increased somewhat, and no evidence of interaction for p-Tau 181 , in which both groups exhibited a decreasing relationship with PD duration.

In this study we examined, in CSF, three AD-related markers and ten inflammation-related proteins in HC and in PD patients with and without FOG. Among those with PD and FOGwhich was carefully characterized clinically and in our motion capture lab -multivariate models showed that Aβ42 was elevated compared to PD-NoFOG cases and to HC. We also found that the anti-inflammatory protein fractalkine was lower in PD-FOG vs PD-NoFOG and HC. While we identified reduced CSF p-tau among both PD groups vs. HC, which was consistent with . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 18, 2020. ; https://doi.org/10.1101/2020.12.16.20248342 doi: medRxiv preprint multiple studies 15 , the changes in Aβ42 and fractalkine were unexpected and in the opposite direction than those seen in comparisons of AD and HC.

Aβ42 is a CSF marker that is low in AD 16 and represents the first marker change 17 that predicts the development of AD pathology. The low levels in AD may reflect increased accumulation in the brain, enhanced clearance, or some other yet unknown mechanisms 18 . Normally, there is a diurnal pattern of CSF amyloid, higher during wakefulness and lower during sleep. This diminishes with age and even more so in AD and relates to sleep disruption which is caused by Aβ42 aggregation seen in animal models 19 . In PD, much of the data on CSF markers comes from early-stage patients in PPMI. Aβ42 CSF levels in early PD (within 2 years of symptom onset) have been shown to be modestly lower than HC (≈9%, in baseline measures) 20, 21, 22 . At levels below a critical value, Aβ42 levels appear to be associated with earlier development and faster decline of cognitive function in PD patients 23 especially in those with REM sleep behavior disorder 24 or the APOE ε4 allele 25 . However, those with CSF Aβ42 levels closer to typical values, relationships between CSF Aβ42 and progression are less clear 26 . The association of low baseline CSF Aβ42 with early dementia in PD has been shown by other investigators as well 27 .

One study suggested an association of low baseline levels to worse motor scores and, in particular, postural instability gait disorder (PIGD) sub score 22 although such findings have not been consistently seen. The neuropathological correlates of lower CSF Aβ42 in PD also remain unclear. Whether those with low levels of CSF Aβ42 represent a subset of PD with coincident AD amyloid accumulation or altered amyloid metabolism in the brain remains to be seen, although previous in vitro animal and clinical cohort studies have suggested the increasingly important role of AD pathology in the development of PD Dementia 28 .

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 18, 2020. ; https://doi.org/10.1101/2020.12.16.20248342 doi: medRxiv preprint

Our results suggest that the associations between lower CSF Aβ42 and incident FOG that hold in newly diagnosed PD patients 13 may not generalize to older or more advanced patients. FOG is also associated with cognitive decline, particularly executive dysfunction 7-9 which is associated with lower Aβ42. Our results in this study would appear to be in opposition to this finding, as we demonstrated higher CSF Aβ42 levels among the PD-FOG group. However, our CSF samples were taken in much later stages of disease than are currently available in studies like PPMI; the mean duration of the disease was 10.4 (±4.8) years and the longest duration in the sample was 23 years. Commensurate with their increased disease duration, these individuals were older than those in the most recent reports from PPMI (71.6 years vs. 61.4 years in PPMI) 22 . Additionally, among the FOG group here, there was no evidence of substantial executive dysfunction -the average MoCA score was 24.1 (results published separately 12 ). This could suggest an increase in CSF levels of Aβ42 in the ensuing time frame, perhaps due to increased amyloid production -or decreased sequestration in the brain -particularly in the PD-FOG group. Our cross-sectional analysis of the relation between CSF Aβ42 and duration of disease in the PD-FOG and PD-NoFOG would also suggest that this increase is specific to those developing FOG, as we found a statistically significant interaction in the relationship between CSF Aβ42 and disease duration:

Aβ42 increased with increasing duration in the PD-FOG group but decreased with increasing duration in the PD-NoFOG group. It has been shown in AD that longitudinal changes of CSF marker levels vary in distinct populations of subjects depending on underlying pathology 29 .

There is limited data on longitudinal changes in levels over time in PD. Data from the PPMI study demonstrated an increase in Aβ42 over 6 and 12 months of follow-up in PD and HC groups which reached significance only at the one year mark compared to baseline (a 4% increase) 30 . This correlated with age in both groups and disease duration in the PD group. They . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 18, 2020. ; https://doi.org/10.1101/2020.12.16.20248342 doi: medRxiv preprint did not examine subgroups such as those with FOG. Irwin et al more recently examined AD markers in PD and HC in a larger number of patients from the PPMI cohort and with a different assay from the prior assessment, this time followed up to three years. In longitudinal analysis they found that the PD cohort had a modestly greater decline in CSF Aβ42 (mean difference = is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 18, 2020. ; https://doi.org/10.1101/2020.12.16.20248342 doi: medRxiv preprint nervous systems. The soluble form, which is measured in this study, has a signaling function specifically through the G-protein-coupled CX3CR1 receptor that resides on microglia 37 .

Fractalkine is known to have anti-inflammatory function under some circumstances as signaling contributes to suppressing microglial activation and maintaining the microglia surveillance phase 38 . As part of this function, it reduces the overproduction of proinflammatory molecules such as inducible nitric oxide synthase, interleukin (IL)-1β, (TNFα), and IL-6 generated by microglia 37,38 . However, in rodent toxin models it has been shown that the exact effects greatly depend on the isoform type (soluble or membrane-bound), animal model (mice or rats, toxin-or proteinopathy-induced), route of toxin administration, time course, specific brain region (striatum, substantia nigra), and cell type 38 . The same is true with regard to α-synuclein models, inflammatory response type depends on the form of α-synuclein (overexpressed wild-type or A53T-mutated form), the specific isoform of fractalkine and the experimental protocol 38 .

Whenever neuroprotective, the soluble, and not the membrane-bound form of fractalkine seems to be responsible for its beneficial role 38 . Similar variation in results in AD models has been reported 39 . In one study, in transgenic mouse models of AD (amyloid precursor protein/-presenilin1 and CX3CR1−/−), fractalkine brought about a decrease in amyloid burden 40 .

One previous CSF study in PD found no difference in fractalkine levels between HC and PD, but it is not clear if participants with FOG were included, which may explain the discrepancy between these and earlier results 41 . The fractalkine/Aβ42 ratio was weakly correlated with PD severity in cross-sectional and longitudinal PD samples. The reason for this may include assay differences, pre-analytical processing, and freeze-thawing effects. In another study, exosomal levels of fractalkine mRNAs were shown to be lower in the CSF of PD patients compared to HC 42 .

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 18, 2020. ; https://doi.org/10.1101/2020.12.16.20248342 doi: medRxiv preprint

The main limitation of this study was the small sample size. Nevertheless, this was the first attempt to examine CSF markers in advanced PD patients with FOG. Another limitation was the cross-sectional nature. Longitudinal studies to examine the trajectory of change of fractalkine and Aβ42 markers will be important.

In conclusion, we examined AD and inflammatory-related CSF markers in advanced PD patients with and without FOG. We found high levels of Aβ42 in PD-FOG, and cross-sectional data which supports an increase over time from early to advanced state in the PD-FOG groups specifically. Longitudinal studies are needed to confirm this. Such results support a previously reported role of Aβ42 in the development of FOG. We also found low levels of fractalkine which might suggest an anti-inflammatory effect. This is the first time an association between fractalkine and FOG has been shown. Whether these changes are specific to FOG or relate to the cognitive change often associated with FOG or simply progression of disease requires further exploration.

The study population included PD patients with FOG (PD-FOG) and without FOG (PD-NoFOG) and healthy controls (HC). Parkinson's participants and HC were recruited from the Emory Movement Disorders and Cognitive Neurology Clinics. Subject recruitment and assessments for those with PD-FOG and PD-NoFOG have been previously described 12 

This study was approved by the institutional review board of Emory University. All subjects provided written informed consent.

CSF (20 mL) was collected using protocols modified from the Alzheimer's Disease Neuroimaging Initiative (ADNI) 46 using 24G Sprotte atraumatic needles and syringe between 8AM and noon without overnight fasting and transferred into two 15 mL polypropylene tubes. performed over 9 days) of 9.4% for TNF-α, 12.9% for MDC, 14.7% for IL-7, 4.8% for IP-10, 12.0% for IL-10, 9.2% for IL-9, and 7.6% for IL-8.

Differences in demographic and clinical variables across groups were assessed with tests of central tendency (chi-square, ANOVA). Levels of 13 putative CSF markers (Table S1) were measured using separate assays and compared across participants with and without PD and with and without FOG using linear models including terms for sex and PD duration. PD duration in years was centered about 0 prior to entry in linear models such that HC were coded with a value of 0, PD patients with above average PD duration were coded with a positive number, and PD patients with below average PD duration were coded with a negative number. The value 0 (representing the average duration) was imputed for one participant with PD for whom this data . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 18, 2020. ; https://doi.org/10.1101/2020.12.16.20248342 doi: medRxiv preprint point was unavailable. P values for factors representing presence of PD and presence of FOG were calculated and adjusted to control Type I error with a Bonferroni-Holm procedure.

In order to assess variation of marker expression with disease duration among individuals with PD, markers that were identified in univariate analyses as varying across groups were entered into multivariate regression analyses with terms for PD duration, FOG, age, and sex. Interaction terms were included to examine whether different relationships between marker expression and disease duration were apparent in PD-NoFOG and PD-FOG. All statistical analyses were performed in R software at alpha=0.05.

Data Availability Statement: Data not available in this manuscript will be shared at the request of other qualified investigators for purposes of replicating procedures and results.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint 11 .5 (5.7) Data are presented as mean ± standard deviation or as N (%). a Significant difference between groups, Chi-squared test. b N=19.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 18, 2020. ; https://doi.org/10.1101/2020.12.16.20248342 doi: medRxiv preprint 15.8 (9.2) c 12.9 (5.0) Data are presented as mean ± standard deviation. a Significant difference between PD and HC, multivariate linear model with Bonferroni-Holm adjustment. b Significant difference between PD-FOG and other groups. c N=18.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 18, 2020. ; Figure 1 . CSF marker levels. Box plots depicting the distribution of the CSF markers (fractalkine, Aβ42, and p-Tau 181 ) across study groups. Boxes and horizontal lines depict ranges Q1-Q3 and median values of the expression of each marker, respectively. Abbreviations: HC, healthy control; PD-NoFOG, PD without FOG; PD-FOG, PD with FOG. P values reflect multivariate linear models controlled for covariates and multiple comparisons.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 18, 2020. ; https://doi.org/10.1101/2020.12.16.20248342 doi: medRxiv preprint Figure 2 . Association between CSF markers (Aβ42, fractalkine, and p-Tau 181 ) and disease duration, stratified by presence of FOG. Light and dark blue lines represent separate linear regressions of marker level onto PD duration for PD-FOG and PD-NoFOG, respectively. Light gray lines represent linear regressions for both groups combined. P values reflect multivariate linear models with terms for age, sex, FOG, PD duration, and interaction between FOG and PD duration.

. CC-BY-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 18, 2020. ; https://doi.org/10.1101/2020.12.16.20248342 doi: medRxiv preprint

Freezing of gait: moving forward on a mysterious clinical phenomenon

The clinical spectrum of freezing of gait in atypical parkinsonism

Physiology of freezing of gait

Neuroimaging advances in Parkinson's disease with freezing of gait: A systematic review

Freezing of Gait can persist after an acute levodopa challenge in

Parkinson's disease

Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans

Amyloid-beta diurnal pattern: possible role of sleep in Alzheimer's disease pathogenesis

The Parkinson's progression markers initiative (PPMI) -establishing a PD biomarker cohort

CSF biomarkers associated with disease heterogeneity in early

Parkinson's disease: the Parkinson's Progression Markers Initiative study

CALHM1 P86L polymorphism modulates CSF Abeta levels in cognitively healthy individuals at risk for Alzheimer's disease

Soluble amyloid-beta levels and late-life depression

CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models

Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression

Glycogen synthase kinase-3 beta (GSK-3beta) signaling: Implications for Parkinson's disease

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases